| 1 | Approve Financial Statements | For |
| 2 | Approve Consolidated Financial Statements | For |
| 3 | Approve Discharge of Directors
| Oppose |
| 4 | Approve the Dividend | For |
| 5 | Approve Transaction with Institut Merieux Re: Amendment to the Services Agreement
| For |
| 6 | Approve Transaction with Fondation Merieux Re: Payment of an Additional Envelope of EUR 12 Million under its Sponsorship Agreement
| For |
| 7 | Approve Transaction with Fondation Merieux Re: Payment of an Additional Envelope of EUR 500,000 under its Sponsorship Agreement
| For |
| 8 | Approve Transaction with Fonds de Dotation bioMerieux Re: Payment of an Initial Endowment of EUR 20 Million to Fonds de Dotation bioMerieux
| For |
| 9 | Elect Alexandre Mérieux - Chair & Chief Executive | Oppose |
| 10 | Elect Marie-Paule Kieny - Non-Executive Director | For |
| 11 | Elect Fanny Letier - Non-Executive Director | For |
| 12 | Approve Remuneration Policy of Corporate Officers
| Oppose |
| 13 | Approve Remuneration Policy of Chairman and CEO
| Oppose |
| 14 | Approve Remuneration Policy of Vice-CEO
| Oppose |
| 15 | Approve Remuneration Policy of Directors
| For |
| 16 | Approve Compensation Report of Corporate Officers
| Oppose |
| 17 | Approve Compensation of Alexandre Merieux, Chairman and CEO
| Oppose |
| 18 | Approve Compensation of Didier Boulud, Vice-CEO
| Oppose |
| 19 | Authorise Share Repurchase | Oppose |
| 20 | Authorize Decrease in Share Capital via Cancellation of Repurchased Shares
| For |
| 21 | Authorize Issuance of Equity or Equity-Linked Securities with Preemptive Rights up to Aggregate Nominal Amount of EUR 4.21 Million
| Oppose |
| 22 | Authorize Issuance of Equity or Equity-Linked Securities without Preemptive Rights up to Aggregate Nominal Amount of EUR 4.21 Million
| Oppose |
| 23 | Approve Issuance of Equity or Equity-Linked Securities for up to 20 Percent of Issued Capital Per Year for Private Placements
| Oppose |
| 24 | Authorize Board to Set Issue Price for 10 Percent Per Year of Issued Capital Pursuant to Issue Authority without Preemptive Rights
| Oppose |
| 25 | Authorize Board to Increase Capital in the Event of Additional Demand Related to Delegation Submitted to Shareholder Vote Under Items 21-23
| Oppose |
| 26 | Authorize Capital Increase of up to 10 Percent of Issued Capital for Contributions in Kind
| Oppose |
| 27 | Authorize Capitalization of Reserves of Up to EUR 4.21 Million for Bonus Issue or Increase in Par Value
| For |
| 28 | Authorize Issuance of Equity Upon Conversion of a Subsidiary's Equity-Linked Securities without Preemptive Rights for Up to EUR 4.21 Million
| Oppose |
| 29 | Authorize up to 10 Percent of Issued Capital for Use in Restricted Stock Plans
| Oppose |
| 30 | Authorize Capital Issuances for Use in Employee Stock Purchase Plans
| Oppose |
| 31 | Eliminate Preemptive Rights Pursuant to Item 30 Above, in Favor of Employees
| Oppose |
| 32 | Set Total Limit for Capital Increase to Result from Issuance Requests Under Items 21-28 and 30 at EUR 4.21 Million
| For |
| 33 | Amend Articles 12, 14, 15 and 17 of Bylaws Re: Remuneration of Corporate Officers; Written Consultation; Corporate Purpose
| For |
| 34 | Approve Change of Corporate Form to Societe Europeenne (SE)
| For |
| 35 | Adopt New Articles of Association | For |
| 36 | Authorize Filing of Required Documents/Other Formalities
| For |
